Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
74 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Vico Therapeutics International from Zaventem, company number BE0746929395, closed financial year 2025 with a result of € -356,083 after tax. For that financial year Vico Therapeutics International recorded a gross margin of € -383,815 and equity of € 87.7 million. Compared with financial year 2024, the result moved from € -826,353 to € -356,083. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ 87.7 million
▲ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -356,083
▲ 57 % less loss than in 2024
Profit after tax over the fiscal year.
€ 5.1 million
▼ 73% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -13.4 million.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 182,133
▼ 11% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -417,624 | € -309,092 | € -734,505 | € -383,815 | ▲ € 350,690 |
| Profit after taxes | € -909,364 | € -9,430,317 | € -826,353 | € -356,083 | ▲ € 470,271 |
| Equity | € 26,675,047 | € 54,319,363 | € 82,890,795 | € 87,728,331 | ▲ 6% |
| Total debts | € 15,973,738 | € 2,501,579 | € 257,749 | € 182,320 | ▼ 29% |
| Cash | € 5,212,459 | € 11,741,804 | € 18,769,393 | € 5,080,544 | ▼ 73% |
| Retained profit | € -2,744,017 | € -12,174,334 | € -13,000,687 | € -13,356,770 | ▼ € 356,083 |
| Bank debt | € 15,000,009 | € 1,700,000 | € 0 | € 0 | |
| Balance sheet total | € 42,648,785 | € 56,820,943 | € 83,148,544 | € 87,910,651 | ▲ 6% |
Key figures of Vico Therapeutics International, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Vico Therapeutics International?
What happened at Vico Therapeutics International in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 356,083. Source: NBB ↗
- Jeroen Vangindertael became a director. NBB
- Joshua Mandel-Brehm became a director. NBB
- Klaus Breiner became a director. NBB
- Felice Isabel van Weegen became a director. NBB
- Primix Bio Ventures became a director. NBB
- Amy Weinfeld Schulman became a director. NBB
- Micah Mackison became a director. NBB
In short
From € 909,364 loss in 2022 to € 356,083 loss in 2025.
A new publication or filing at Vico Therapeutics International? We notify you, reason included.
Follow Vico Therapeutics InternationalDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of AvH Growth Capital comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Vico Therapeutics InternationalBehind Vico Therapeutics International are Jeroen Vangindertael, Joshua Mandel-Brehm, Klaus Breiner, Felice Isabel van Weegen, Primix Bio Ventures and Amy Weinfeld Schulman. The shares are held by AvH Growth Capital (11.2%). It owns 100% of Vico Therapeutics US Inc. and 100% of Vico Therapeutics B.V. itself.
Directors
According to the 2025 annual accounts
since 2023
Joshua Mandel-Brehm
Director
since 2023
Klaus Breiner
Director
since 2023
Felice Isabel van Weegen
Director
since 2023
since 2023
Amy Weinfeld Schulman
Director
since 2023
Micah Mackison
Director
since 2023
Martijn Kleijwegt
Director
since 2023
Anders Hinsby
Director
since 2023
Pascal Louis Droller Rémi
Director
since 2023
Shareholders
11.2%
Participations
Vico Therapeutics US Inc.
100%
Vico Therapeutics B.V.
100%
Establishments
Establishment units
Physical locations of this company
Da Vincilaan 1
1930 Zaventem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 74 companies are registered at this address.
All companies at this address →ALFA LAVAL BENELUX
€ 4.8 million gross margin · 2025
Association of Belgian Travel Organisers
ORTHO - CLINICAL DIAGNOSTICS
€ 12.7 million revenue · 2025
FIRST STOP EUROPE
€ 8 million revenue · 2025
JOMIROU
€ -17,491 gross margin · 2024
+69 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0746.929.395
- VAT number
- BE 0746.929.395
- Registered office
- Da Vincilaan 1, 1930 Zaventem
- Names & denominations
- Vico Therapeutics International
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 May 2020
- Peppol
- Active · Active since 27 Mar 2026